Creative Biolabs has expanded its specialized antibody portfolio to include new reagents targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1. This expansion addresses a critical need in virology, immunology, vaccine development, and diagnostic assay development, where research antibodies against defined viral proteins are essential for studying viral entry, epitope recognition, immune responses, and diagnostic assay development. The addition of these antibodies provides researchers with more options to investigate the complex biology of human retroviruses, which continue to pose significant global health challenges.
At the forefront of HIV research is the study of the viral envelope, particularly the gp140 protein, an uncleaved ectodomain of the HIV-1 envelope glycoprotein. This protein is a primary target for broadly neutralizing antibodies and vaccine design. Creative Biolabs now offers an anti-gp140 HIV-1 antibody for research applications involving HIV-1 envelope biology, antigen recognition, and related assay development. This reagent is expected to facilitate studies aimed at understanding how the virus enters cells and how the immune system recognizes it, which is crucial for developing effective vaccines and therapies.
While HIV-1 accounts for the majority of global infections, HIV-2 presents unique clinical challenges due to its distinct genetic makeup and different disease progression rates. Because gp36 is an HIV-2 envelope-associated antigen, antibodies targeting gp36 can be useful research tools for studying antigen recognition, cross-reactivity, and the development and evaluation of HIV-2-focused assay concepts. The availability of such tools is vital for differentiating between HIV-1 and HIV-2 infections and for developing accurate diagnostic tests, which is particularly important in regions where both viruses co-circulate.
Beyond HIV, the human T-cell lymphotropic virus type 1 (HTLV-1) represents another significant retroviral threat, being the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy. HTLV-1 gag p19 is a viral core protein commonly investigated in studies of HTLV-1 biology, viral protein expression, and immune recognition. Creative Biolabs' anti-HTLV-1 gag p19 antibody is intended for research applications such as Western blot, ELISA, and immunohistochemistry, supporting research into HTLV-1 pathogenesis and related virology questions. This antibody enables researchers to detect and quantify the p19 protein, which is important for understanding viral replication and the immune response to HTLV-1.
"Retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats," said a senior scientist at Creative Biolabs. "By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, we aim to give researchers additional options for studying viral proteins, antigen recognition, and assay development." This strategic expansion underscores the company's commitment to supporting the scientific community in tackling infectious diseases.
Creative Biolabs provides retrovirus-targeted antibodies and custom antibody development services for research applications in virology and infectious disease. For more information about the complete range of retrovirus-targeted antibodies and custom services, please visit https://www.antibody-creativebiolabs.com/. For research use only. Not for use in diagnostic or therapeutic procedures.
